185 related articles for article (PubMed ID: 37125259)
1. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA.
Rejeski K; Greco R; Onida F; Sánchez-Ortega I; Bonini C; Sureda A; Gribben JG; Yakoub-Agha I; Subklewe M
Hemasphere; 2023 May; 7(5):e889. PubMed ID: 37125259
[TBL] [Abstract][Full Text] [Related]
2. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
Rejeski K; Subklewe M; Aljurf M; Bachy E; Balduzzi A; Barba P; Bruno B; Benjamin R; Carrabba MG; Chabannon C; Ciceri F; Corradini P; Delgado J; Di Blasi R; Greco R; Houot R; Iacoboni G; Jäger U; Kersten MJ; Mielke S; Nagler A; Onida F; Peric Z; Roddie C; Ruggeri A; Sánchez-Guijo F; Sánchez-Ortega I; Schneidawind D; Schubert ML; Snowden JA; Thieblemont C; Topp M; Zinzani PL; Gribben JG; Bonini C; Sureda A; Yakoub-Agha I
Blood; 2023 Sep; 142(10):865-877. PubMed ID: 37300386
[TBL] [Abstract][Full Text] [Related]
3. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K; Wang Y; Hansen DK; Iacoboni G; Bachy E; Bansal R; Penack O; Müller F; Bethge W; Munoz J; Mohty R; Bücklein VL; Barba P; Locke FL; Lin Y; Jain MD; Subklewe M
Blood Adv; 2024 Apr; 8(8):1857-1868. PubMed ID: 38181508
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity.
Liang EC; Rejeski K; Fei T; Albittar A; Huang JJ; Portuguese AJ; Wu Q; Raj S; Subklewe M; Shouval R; Gauthier J
Bone Marrow Transplant; 2024 Apr; ():. PubMed ID: 38627450
[TBL] [Abstract][Full Text] [Related]
5. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
[TBL] [Abstract][Full Text] [Related]
6. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management.
Rejeski K; Jain MD; Shah NN; Perales MA; Subklewe M
Lancet Haematol; 2024 May; ():. PubMed ID: 38734026
[TBL] [Abstract][Full Text] [Related]
7. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
[TBL] [Abstract][Full Text] [Related]
8. How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy.
Davis JA; McGann M; Marini J; Hashmi H
Expert Rev Anticancer Ther; 2024 Apr; ():1-4. PubMed ID: 38626305
[No Abstract] [Full Text] [Related]
9. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.
Beyar-Katz O; Perry C; On YB; Amit O; Gutwein O; Wolach O; Kedar R; Pikovsky O; Avivi I; Gold R; Ben-Ezra J; Shasha D; Ami RB; Ram R
Ann Hematol; 2022 Aug; 101(8):1769-1776. PubMed ID: 35731278
[TBL] [Abstract][Full Text] [Related]
11. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy.
Xing L; Wang Y; Liu H; Gao S; Shao Q; Yue L; Liu Z; Wang H; Shao Z; Fu R
Front Oncol; 2021; 11():798352. PubMed ID: 35004324
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic CD34
Lipsitt A; Beattie L; Harstead E; Li Y; Goorha S; Maron G; Gottschalk S; Triplett B; Naik S
Pediatr Blood Cancer; 2023 Mar; 70(3):e30166. PubMed ID: 36565276
[TBL] [Abstract][Full Text] [Related]
14. The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities.
Ellard R; Kenyon M; Hutt D; Aerts E; de Ruijter M; Chabannon C; Mohty M; Montoto S; Wallhult E; Murray J
Clin Hematol Int; 2022 Sep; 4(3):75-88. PubMed ID: 36131128
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report.
Baur R; Jitschin R; Kharboutli S; Stoll A; Völkl S; Büttner-Herold M; Schmidt D; Rösler W; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272307
[TBL] [Abstract][Full Text] [Related]
16. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
18. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.
Mahmoudjafari Z; Hawks KG; Hsieh AA; Plesca D; Gatwood KS; Culos KA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):26-33. PubMed ID: 30266675
[TBL] [Abstract][Full Text] [Related]
19. A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy.
Zhang Y; Tang W; Li Y; Yi Y; Yu Z; Liu X; Zhang L; Zheng Y; Niu T
Int Immunopharmacol; 2023 Jan; 114():109592. PubMed ID: 36700772
[TBL] [Abstract][Full Text] [Related]
20. High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review.
Accorsi Buttini E; Farina M; Lorenzi L; Polverelli N; Radici V; Morello E; Colnaghi F; Almici C; Ferrari E; Bianchetti A; Leoni A; Re F; Bosio K; Bernardi S; Malagola M; Re A; Russo D
Front Oncol; 2023; 13():1036455. PubMed ID: 36741006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
